Dunia
Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal
Bloomberg · 1 jam lalu
Sumber: Bloomberg · 1 jam lalu
Recap • TITIR
- Eli Lilly agrees to buy Calytrix Bio for up to $1.5 billion.
- Deal is part of Lilly’s $32 billion acquisition wave in 2026.
- Purchased company focuses on cancer and immunology businesses.
- Sam Fazeli, Bloomberg Intelligence, analyzes biotech and AI’s role in M&A.
- Lilly’s acquisitions aim to expand cancer and immunology capabilities.
Recap singkat dari artikel aslinya. Bisa aja kurang pas — baca sumber aslinya buat versi lengkap.
Ikuti berita pentingKami kabari hanya kalau isunya benar-benar ramai.